Presence of p16 hypermethylation and Epstein-Barr virus infection in transplant-associated hematolymphoid neoplasm of the skin

Journal of the American Academy of Dermatology

Volumn 55, Issue 5, 2006, Pages 794-798

  Arbiser, Jack L ^a,c   Mann, Karen P ^b   Losken, Elizabeth M ^a   Cohen, Cynthia ^b   Reddy, Kalpana ^a,c   Kokko, Kenneth ^d   Pollack, Brian ^a   Fan, Chung Yang ^e   O'Reilly, Fiona ^a  

^a Wake Forest U   (United States)

^b Pathology and Laboratory Medicine

^c ATLANTA VA MEDICAL CENTER   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF ARKANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN HEAVY CHAIN; METHOTREXATE; PROTEIN P16INK4A; RAPAMYCIN; REACTIVE OXYGEN METABOLITE; T LYMPHOCYTE RECEPTOR; VINCRISTINE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; DNA METHYLATION; EPSTEIN BARR VIRUS; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; IN SITU HYBRIDIZATION; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL; SKIN BIOPSY; SKIN LYMPHOMA; TUMOR CLASSIFICATION; TUMOR SUPPRESSOR GENE; VIRUS INFECTION;

ADULT; DNA METHYLATION; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; GENES, P16; HUMANS; KIDNEY TRANSPLANTATION; LYMPHOMA; SKIN NEOPLASMS;

EID: 33749652741     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2006.06.043     Document Type: Article

References (11)

1. Arbiser J.L., Fan C.Y., Su X., Van Emburgh B.O., Cerimele F., Miller M.S., et al. Involvement of p53 and p16 tumor suppressor genes in recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma. J Invest Dermatol 123 (2004) 788-790
2. Elstrom R.L., Andreadis C., Aqui N.A., Ahya V.N., Bloom R.D., Brozena S.C., et al. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 6 (2006) 569-576
3. Kang G.H., Lee S., Kim W.H., Lee H.W., Kim J.C., Rhyu M.G., et al. Epstein-Barr virus-positive gastric carcinoma demonstrates frequent aberrant methylation of multiple genes and constitutes CpG island methylator phenotype-positive gastric carcinoma. Am J Pathol 160 (2002) 787-794
4. Vo Q.N., Geradts J., Gulley M.L., Boudreau D.A., Bravo J.C., and Schneider B.G. Epstein-Barr virus in gastric adenocarcinomas: association with ethnicity and CDKN2A promoter methylation. J Clin Pathol 55 (2002) 669-675
5. Tong J.H., Tsang R.K., Lo K.W., Woo J.K., Kwong J., Chan M.W., et al. Quantitative Epstein-Barr virus DNA analysis and detection of gene promoter hypermethylation in nasopharyngeal (NP) brushing samples from patients with NP carcinoma. Clin Cancer Res 8 (2002) 2612-2619
6. Arbiser J.L., Moses M.A., Fernandez C.A., Ghiso N., Cao Y., Klauber N., et al. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc Natl Acad Sci U S A 94 (1997) 861-866
7. Govindarajan B., Klafter R., Miller M.S., Mansur C., Mizesko M., Bai X., et al. Reactive oxygen-induced carcinogenesis causes hypermethylation of p16(Ink4a) and activation of MAP kinase. Mol Med 8 (2002) 1-8
8. Arbiser J.L. Molecular regulation of angiogenesis and tumorigenesis by signal transduction pathways: evidence of predictable and reproducible patterns of synergy in diverse neoplasms. Semin Cancer Biol 14 (2004) 81-91
9. Cerimele F., Battle T., Lynch R., Frank D.A., Murad E., Cohen C., et al. Reactive oxygen signaling and MAPK activation distinguish Epstein-Barr virus (EBV)-positive versus EBV-negative Burkitt's lymphoma. Proc Natl Acad Sci U S A 102 (2005) 175-179
10. Segura-Pacheco B., Trejo-Becerril C., Perez-Cardenas E., Taja-Chayeb L., Mariscal I., Chavez A., et al. Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. Clin Cancer Res 9 (2003) 1596-1603
11. Kantarjian H., Issa J.P., Rosenfeld C.S., Bennett J.M., Albitar M., Dipersio J., et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106 (2001) 1794-1803